Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
-
Published:2022-07-14
Issue:2
Volume:387
Page:132-147
-
ISSN:0028-4793
-
Container-title:New England Journal of Medicine
-
language:en
-
Short-container-title:N Engl J Med
Author:
Richardson Paul G.1, Jacobus Susanna J.1, Weller Edie A.1, Hassoun Hani1, Lonial Sagar1, Raje Noopur S.1, Medvedova Eva1, McCarthy Philip L.1, Libby Edward N.1, Voorhees Peter M.1, Orlowski Robert Z.1, Anderson Larry D.1, Zonder Jeffrey A.1, Milner Carter P.1, Gasparetto Cristina1, Agha Mounzer E.1, Khan Abdullah M.1, Hurd David D.1, Gowin Krisstina1, Kamble Rammurti T.1, Jagannath Sundar1, Nathwani Nitya1, Alsina Melissa1, Cornell R. Frank1, Hashmi Hamza1, Campagnaro Erica L.1, Andreescu Astrid C.1, Gentile Teresa1, Liedtke Michaela1, Godby Kelly N.1, Cohen Adam D.1, Openshaw Thomas H.1, Pasquini Marcelo C.1ORCID, Giralt Sergio A.1, Kaufman Jonathan L.1, Yee Andrew J.1, Scott Emma1, Torka Pallawi1, Foley Amy1, Fulciniti Mariateresa1, Hebert Kyle1, Samur Mehmet K.1, Masone Kelly1, Maglio Michelle E.1, Zeytoonjian Andrea A.1, Nadeem Omar1, Schlossman Robert L.1, Laubach Jacob P.1, Paba-Prada Claudia1, Ghobrial Irene M.1, Perrot Aurore1, Moreau Philippe1, Avet-Loiseau Hervé1, Attal Michel1, Anderson Kenneth C.1, Munshi Nikhil C.1
Affiliation:
1. From the Department of Medical Oncology, Dana–Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana–Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children’s Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y....
Funder
Takeda Pharmaceuticals North America RJ Corman Multiple Myeloma Research Fund National Institutes of Health National Heart, Lung, and Blood Institute National Cancer Institute Celgene/Bristol Myers Squibb
Publisher
Massachusetts Medical Society
Reference37 articles.
1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma 2. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial 3. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma 4. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial 5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Cited by
242 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|